Full Press Release Details
Silo Pharma Announces
Share Buyback Program
Sarasota, FL, February
23, 2026- Silo Pharma, Inc. (Nasdaq: SILO) ("the Company"),
a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced
that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock.
The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with
the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had 13,318,273
shares of common stock outstanding as of November 13, 2025, as reported in its Quarterly Report for the period ended September 30, 2025.
the current capital market conditions should allow us to capture additional value for all shareholders through this measured buyback program.
Our Board of Directors and executive management team remain committed to delivering value to our
shareholders," said Eric Weisblum, Chief Executive Officer.
The timing, number of
shares repurchased, and prices paid for the stock under this program will depend on market conditions and corporate and regulatory limitations,
including blackout period restrictions. The repurchase program does not obligate the Company to acquire any specific number of shares,
and it may be suspended or discontinued at the Company's discretion.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical
and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric
disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as
SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis.
Silo's research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains "forward-looking
statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
These statements are identified using words "could", "believe", "anticipate", "intend",
"estimate", "expect", "may", "continue", "predict", "potential",
and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties,
and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such
statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future
economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the
Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although
the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that
such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking
information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this
press release or to reflect the occurrence of unanticipated events except as required by law.